Andrew Alt, PhD

University of Michigan, Michigan, United States

Dr. Andy Alt, PhD is the Director of the Center for Chemical Genomics at the University of Michigan. Dr. Alt has over 15 years of early-phase drug discovery experience ranging from “big pharma” (Eli Lilly, Pfizer, Bristol-Myers Squibb) to biotech (EPIX Pharmaceuticals, Arvinas Inc.), prior to joining the Michigan Drug Discovery group in 2018. Best known for his work on allosteric modulators of GPCRs and other receptor proteins, Dr. Alt led the discovery of the first reported positive allosteric modulators of D1 dopamine receptors, toll-like receptors (TLRs), delta opioid receptors, mu opioid receptors, and nociceptin receptors (ORL1).

Disclosure information not submitted.

Presentation(s):

• Academic Drug Discovery

  Tuesday, February 6, 2024
  1:00 PM – 2:00 PM EST